TGF-ß/Smad signaling in renal fibrosis

Frontiers in Physiology

Volumn 6, Issue MAR, 2015, Pages

  Meng, Xiao Ming ^a   Tang, Patrick Ming Kuen ^b   Li, Jun ^a   Lan, Hui Yao ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

mechanisms; renal fibrosis; Smads mediators; TGF ; Therapeutics

Indexed keywords

MICRORNA 192; MICRORNA 200; MICRORNA 21; MICRORNA 29; PROTEIN INHIBITOR; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

BIOACCUMULATION; BIOSYNTHESIS; CELL ACTIVATION; CELL TRANSDIFFERENTIATION; CHRONIC KIDNEY DISEASE; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; KIDNEY FIBROSIS; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN TRANSPORT; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84926452481     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00082     Document Type: Review

References (120)

1. Afrakhte, M., Moren, A., Jossan, S., Itoh, S., Sampath, K., Westermark, B., et al. (1998). Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem. Biophys. Res. Commun. 249, 505-511. doi: 10.1006/bbrc.1998.9170
2. Ai, J., Nie, J., He, J., Guo, Q., Li, M., Lei, Y., et al. (2014). GQ5 hinders renal fibrosis in obstructive nephropathy by selectively inhibiting TGF-beta-induced Smad3 phosphorylation. J. Am. Soc. Nephrol. doi: 10.1681/ASN.2014040363. [Epub ahead of print].
3. Allison, S. J. (2013). Fibrosis: the source of myofibroblasts in kidney fibrosis. Nat. Rev. Nephrol. 9, 494. doi: 10.1038/nrneph.2013.141
4. Attisano, L., and Wrana, J. L. (2002). Signal transduction by the TGF-beta superfamily. Science 296, 1646-1647. doi: 10.1126/science.1071809
5. Border, W. A., and Noble, N. A. (1998). Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 54, 1390-1391. doi: 10.1046/j.1523-1755.1998.00127.x
6. Bottinger, E. P., and Bitzer, M. (2002). TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 13, 2600-2610. doi: 10.1097/01.ASN.0000033611.79556.AE
7. Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., et al. (2012). MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra118. doi: 10.1126/scitranslmed.3003205
8. Chen, H. Y., Huang, X. R., Wang, W., Li, J. H., Heuchel, R. L., Chung, A. C., et al. (2011). The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60, 590-601. doi: 10.2337/db10-0403
9. Chen, H. Y., Zhong, X., Huang, X. R., Meng, X. M., You, Y., Chung, A. C., et al. (2014). MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 22, 842-853. doi: 10.1038/mt.2013.235
10. Chen, S. J., Yuan, W., Mori, Y., Levenson, A., Trojanowska, M., and Varga, J. (1999). Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J. Invest. Dermatol. 112, 49-57. doi: 10.1046/j.1523-1747.1999.00477.x
11. Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., and Kopp, J. B. (2007). Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906-913. doi: 10.2215/CJN.01050207
12. Choi, M. E., Ding, Y., and Kim, S. I. (2012). TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin. Nephrol. 32, 244-252. doi: 10.1016/j.semnephrol.2012.04.003
13. Chung, A. C., Dong, Y., Yang, W., Zhong, X., Li, R., and Lan, H. Y. (2013a). Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol. Ther. 21, 388-398. doi: 10.1038/mt.2012.251
14. Chung, A. C., Huang, X. R., Meng, X., and Lan, H. Y. (2010a). miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21, 1317-1325. doi: 10.1681/ASN.2010020134
15. Chung, A. C., Huang, X. R., Zhou, L., Heuchel, R., Lai, K. N., and Lan, H. Y. (2009). Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol. Dial. Transplant 24, 1443-1454. doi: 10.1093/ndt/gfn699
16. Chung, A. C., Yu, X., and Lan, H. Y. (2013b). MicroRNA and nephropathy: emerging concepts. Int. J. Nephrol. Renovasc. Dis. 6, 169-179. doi: 10.2147/IJNRD.S37885
17. Chung, A. C., Zhang, H., Kong, Y. Z., Tan, J. J., Huang, X. R., Kopp, J. B., et al. (2010b). Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J. Am. Soc. Nephrol. 21, 249-260. doi: 10.1681/ASN.2009010018
18. Dennler, S., Itoh, S., Vivien, D., Ten Dijke, P., Huet, S., and Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091-3100. doi: 10.1093/emboj/17.11.3091
19. Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584. doi: 10.1038/nature02006
20. Doi, S., Zou, Y., Togao, O., Pastor, J. V., John, G. B., Wang, L., et al. (2011). Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 286, 8655-8665. doi: 10.1074/jbc.M110.174037
21. Du, B., Ma, L. M., Huang, M. B., Zhou, H., Huang, H. L., Shao, P., et al. (2010). High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584, 811-816. doi: 10.1016/j.febslet.2009.12.053
22. Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., et al. (2001). Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480. doi: 10.1074/jbc.C100008200
23. Eddy, A. A., and Neilson, E. G. (2006). Chronic kidney disease progression. J. Am. Soc. Nephrol. 17, 2964-2966. doi: 10.1681/ASN.2006070704
24. Evans, R. A., Tian, Y. C., Steadman, R., and Phillips, A. O. (2003). TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp. Cell Res. 282, 90-100. doi: 10.1016/S0014-4827(02)00015-0
25. Fan, J. M., Ng, Y. Y., Hill, P. A., Nikolic-Paterson, D. J., Mu, W., Atkins, R. C., et al. (1999). Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int. 56, 1455-1467. doi: 10.1046/j.1523-1755.1999.00656.x
26. Fujimoto, M., Maezawa, Y., Yokote, K., Joh, K., Kobayashi, K., Kawamura, H., et al. (2003). Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305, 1002-1007. doi: 10.1016/S0006-291X(03)00885-4
27. Fukasawa, H., Yamamoto, T., Togawa, A., Ohashi, N., Fujigaki, Y., Oda, T., et al. (2004). Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc. Natl. Acad. Sci. U.S.A. 101, 8687-8692. doi: 10.1073/pnas.0400035101
28. Godwin, J. G., Ge, X., Stephan, K., Jurisch, A., Tullius, S. G., and Iacomini, J. (2010). Identification of a microRNA signature of renal ischemia reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 107, 14339-14344. doi: 10.1073/pnas.0912701107
29. Hong, K. M., Belperio, J. A., Keane, M. P., Burdick, M. D., and Strieter, R. M. (2007). Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282, 22910-22920. doi: 10.1074/jbc.M703597200
30. Hou, C. C., Wang, W., Huang, X. R., Fu, P., Chen, T. H., Sheikh-Hamad, D., et al. (2005). Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am. J. Pathol. 166, 761-771. doi: 10.1016/S0002-9440(10)62297-3
31. Howe, E. N., Cochrane, D. R., and Richer, J. K. (2012). The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J. Mammary Gland Biol. Neoplasia 17, 65-77. doi: 10.1007/s10911-012-9244-6
32. Hruska, K. A., Guo, G., Wozniak, M., Martin, D., Miller, S., Liapis, H., et al. (2000). Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am. J. Physiol. Renal Physiol. 279, F130-F143.
33. Huang, X. R., Chung, A. C., Wang, X. J., Lai, K. N., and Lan, H. Y. (2008a). Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am. J. Physiol. Renal Physiol. 295, F118-F127. doi: 10.1152/ajprenal.00021.2008
34. Huang, X. R., Chung, A. C., Zhou, L., Wang, X. J., and Lan, H. Y. (2008b). Latent TGF-beta1 protects against crescentic glomerulonephritis. J. Am. Soc. Nephrol. 19, 233-242. doi: 10.1681/ASN.2007040484
35. Ka, S. M., Huang, X. R., Lan, H. Y., Tsai, P. Y., Yang, S. M., Shui, H. A., et al. (2007). Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J. Am. Soc. Nephrol. 18, 1777-1788. doi: 10.1681/ASN.2006080901
36. Ka, S. M., Yeh, Y. C., Huang, X. R., Chao, T. K., Hung, Y. J., Yu, C. P., et al. (2012). Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 55, 509-519. doi: 10.1007/s00125-011-2364-5
37. Kantharidis, P., Wang, B., Carew, R. M., and Lan, H. Y. (2011). Diabetes complications: the microRNA perspective. Diabetes 60, 1832-1837. doi: 10.2337/db11-0082
38. Kato, M., Arce, L., Wang, M., Putta, S., Lanting, L., and Natarajan, R. (2011). A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int. 80, 358-368. doi: 10.1038/ki.2011.43
39. Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., et al. (2007). MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U.S.A. 104, 3432-3437. doi: 10.1073/pnas.0611192104
40. Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., et al. (2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6, 1365-1375. doi: 10.1016/S1097-2765(00)00134-9
41. Kim, S. G., Kim, H. A., Jong, H. S., Park, J. H., Kim, N. K., Hong, S. H., et al. (2005). The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3. Mol. Biol. Cell 16, 4672-4683. doi: 10.1091/mbc.E05-01-0054
42. Kopp, J. B., Factor, V. M., Mozes, M., Nagy, P., Sanderson, N., Bottinger, E. P., et al. (1996). Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Invest. 74, 991-1003.
43. Korpal, M., Lee, E. S., Hu, G., and Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910-14914. doi: 10.1074/jbc.C800074200
44. Kriegel, A. J., Liu, Y., Cohen, B., Usa, K., and Liang, M. (2012). MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis. Physiol. Genomics 44, 259-267. doi: 10.1152/physiolgenomics.00173.2011
45. Krupa, A., Jenkins, R., Luo, D. D., Lewis, A., Phillips, A., and Fraser, D. (2010). Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 438-447. doi: 10.1681/ASN.2009050530
46. Lan, H. Y., and Chung, A. C. (2012). TGF-beta/Smad signaling in kidney disease. Semin. Nephrol. 32, 236-243. doi: 10.1016/j.semnephrol.2012.04.002
47. Lan, H. Y., Mu, W., Tomita, N., Huang, X. R., Li, J. H., Zhu, H. J., et al. (2003). Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J. Am. Soc. Nephrol. 14, 1535-1548. doi: 10.1097/01.ASN.0000067632.04658.B8
48. LeBleu, V. S., Taduri, G., O'Connell, J., Teng, Y., Cooke, V. G., Woda, C., et al. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053. doi: 10.1038/nm.3218
49. Li, J. H., Huang, X. R., Zhu, H. J., Johnson, R., and Lan, H. Y. (2003). Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 63, 2010-2019. doi: 10.1046/j.1523-1755.2003.00016.x
50. Li, J. H., Huang, X. R., Zhu, H. J., Oldfield, M., Cooper, M., Truong, L. D., et al. (2004). Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 18, 176-178. doi: 10.1096/fj.02-1117fje
51. Li, J., Qu, X., Yao, J., Caruana, G., Ricardo, S. D., Yamamoto, Y., et al. (2010). Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59, 2612-2624. doi: 10.2337/db09-1631
52. Li, Y., Tan, X., Dai, C., Stolz, D. B., Wang, D., and Liu, Y. (2009). Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 1907-1918. doi: 10.1681/ASN.2008090930
53. Liu, F. Y., Li, X. Z., Peng, Y. M., Liu, H., and Liu, Y. H. (2008). Arkadia regulates TGF-beta signaling during renal tubular epithelial to mesenchymal cell transition. Kidney Int. 73, 588-594. doi: 10.1038/sj.ki.5002713
54. Liu, G. X., Li, Y. Q., Huang, X. R., Wei, L., Chen, H. Y., Shi, Y. J., et al. (2013). Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-beta/Smad3-NF.kappaB-dependent mechanisms in mice. PLoS ONE 8:e53573. doi: 10.1371/journal.pone.0053573
55. Liu, G. X., Li, Y. Q., Huang, X. R., Wei, L. H., Zhang, Y., Feng, M., et al. (2014). Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clin. Sci. 127, 195-208. doi: 10.1042/CS20130706
56. Liu, Y. (2010). New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212-222. doi: 10.1681/ASN.2008121226
57. Liu, Y., Taylor, N. E., Lu, L., Usa, K., Cowley, A. W. Jr., Ferreri, N. R., et al. (2010). Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 55, 974-982. doi: 10.1161/HYPERTENSIONAHA.109.144428
58. Liu, Z., Huang, X. R., and Lan, H. Y. (2012). Smad3 mediates ANG II-induced hypertensive kidney disease in mice. Am. J. Physiol. Renal Physiol. 302, F986-F997. doi: 10.1152/ajprenal.00595.2011
59. Loeffler, I., and Wolf, G. (2014). Transforming growth factor-beta and the progression of renal disease. Nephrol. Dial. Transplant. 29(Suppl. 1), i37-i45. doi: 10.1093/ndt/gft267
60. Lopez-Hernandez, F. J., and Lopez-Novoa, J. M. (2012). Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 347, 141-154. doi: 10.1007/s00441-011-1275-6
61. Luo, D. D., Phillips, A., and Fraser, D. (2010). Bone morphogenetic protein-7 inhibits proximal tubular epithelial cell Smad3 signaling via increased SnoN expression. Am. J. Pathol. 176, 1139-1147. doi: 10.2353/ajpath.2010.090459
62. Lyons, R. M., Gentry, L. E., Purchio, A. F., and Moses, H. L. (1990). Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J. Cell Biol. 110, 1361-1367. doi: 10.1083/jcb.110.4.1361
63. Massague, J., and Wotton, D. (2000). Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19, 1745-1754. doi: 10.1093/emboj/19.8.1745
64. Meng, X. M., Chung, A. C., and Lan, H. Y. (2013). Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin. Sci. 124, 243-254. doi: 10.1042/CS20120252
65. Meng, X. M., Huang, X. R., Chung, A. C., Qin, W., Shao, X., Igarashi, P., et al. (2010). Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21, 1477-1487. doi: 10.1681/ASN.2009121244
66. Meng, X. M., Huang, X. R., Xiao, J., Chen, H. Y., Zhong, X., Chung, A. C., et al. (2012a). Diverse roles of TGF-beta receptor II in renal fibrosis and inflammation in vivo and in vitro. J. Pathol. 227, 175-188. doi: 10.1002/path.3976
67. Meng, X. M., Huang, X. R., Xiao, J., Chung, A. C., Qin, W., Chen, H. Y., et al. (2012b). Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 81, 266-279. doi: 10.1038/ki.2011.327
68. Meng, X. M., Nikolic-Paterson, D. J., and Lan, H. Y. (2014). Inflammatory processes in renal fibrosis. Nat. Rev. Nephrol. 10, 493-503. doi: 10.1038/nrneph.2014.114
69. Midgley, A. C., Rogers, M., Hallett, M. B., Clayton, A., Bowen, T., Phillips, A. O., et al. (2013). Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J. Biol. Chem. 288, 14824-14838. doi: 10.1074/jbc.M113.451336
70. Moon, J. A., Kim, H. T., Cho, I. S., Sheen, Y. Y., and Kim, D. K. (2006). IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70, 1234-1243. doi: 10.1038/sj.ki.5001775
71. Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., Wu, J., et al. (1999). The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328. doi: 10.1016/S0092-8674(00)80545-0
72. Murakami, K., Takemura, T., Hino, S., and Yoshioka, K. (1997). Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr. Nephrol. 11, 334-336. doi: 10.1007/s004670050289
73. Ng, Y. Y., Chen, Y. M., Tsai, T. J., Lan, X. R., Yang, W. C., and Lan, H. Y. (2009). Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am. J. Nephrol. 29, 43-53. doi: 10.1159/000150600
74. Nikolic-Paterson, D. J., Wang, S., and Lan, H. Y. (2014). Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int. Suppl. 4, 34-38. doi: 10.1038/kisup.2014.7
75. Oba, S., Kumano, S., Suzuki, E., Nishimatsu, H., Takahashi, M., Takamori, H., et al. (2010). miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE 5:e13614. doi: 10.1371/journal.pone.0013614
76. Petersen, M., Thorikay, M., Deckers, M., van Dinther, M., Grygielko, E. T., Gellibert, F., et al. (2008). Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705-715. doi: 10.1038/sj.ki.5002717
77. Phanish, M. K., Wahab, N. A., Colville-Nash, P., Hendry, B. M., and Dockrell, M. E. (2006). The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem. J. 393, 601-607. doi: 10.1042/BJ20051106
78. Piek, E., Ju, W. J., Heyer, J., Escalante-Alcalde, D., Stewart, C. L., Weinstein, M., et al. (2001). Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276, 19945-19953. doi: 10.1074/jbc.M102382200
79. Putta, S., Lanting, L., Sun, G., Lawson, G., Kato, M., and Natarajan, R. (2012). Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 23, 458-469. doi: 10.1681/ASN.2011050485
80. Qin, W., Chung, A. C., Huang, X. R., Meng, X. M., Hui, D. S., Yu, C. M., et al. (2011). TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462-1474. doi: 10.1681/ASN.2010121308
81. Samarakoon, R., Overstreet, J. M., Higgins, S. P., and Higgins, P. J. (2012). TGF-beta1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347, 117-128. doi: 10.1007/s00441-011-1181-y
82. Sanderson, N., Factor, V., Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., et al. (1995). Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. U.S.A. 92, 2572-2576. doi: 10.1073/pnas.92.7.2572
83. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B., and Ooshima, A. (2003). Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486-1494. doi: 10.1172/JCI200319270
84. Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., et al. (2011). Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144-1151. doi: 10.1681/ASN.2010101049
85. Shen, N., Lin, H., Wu, T., Wang, D., Wang, W., Xie, H., et al. (2013). Inhibition of TGF-beta1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. Kidney Int. 84, 64-77. doi: 10.1038/ki.2013.82
86. Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700. doi: 10.1016/S0092-8674(03)00432-X
87. Sugimoto, H., Grahovac, G., Zeisberg, M., and Kalluri, R. (2007). Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825-1833. doi: 10.2337/db06-1226
88. Tampe, D., and Zeisberg, M. (2014). Potential approaches to reverse or repair renal fibrosis. Nat. Rev. Nephrol. 10, 226-237. doi: 10.1038/nrneph.2014.14
89. Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R., Peters, H., et al. (2011). A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243. doi: 10.1038/ki.2011.33
90. Tsakas, S., and Goumenos, D. S. (2006). Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am. J. Nephrol. 26, 186-193. doi: 10.1159/000093178
91. Tsuchida, K., Zhu, Y., Siva, S., Dunn, S. R., and Sharma, K. (2003). Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int. 63, 2000-2009. doi: 10.1046/j.1523-1755.2003.00009.x
92. van Rooij, E., Sutherland, L. B., Thatcher, J. E., Dimaio, J. M., Naseem, R. H., Marshall, W. S., et al. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027-13032. doi: 10.1073/pnas.0805038105
93. Vindevoghel, L., Lechleider, R. J., Kon, A., de Caestecker, M. P., Uitto, J., Roberts, A. B., et al. (1998). SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc. Natl. Acad. Sci. U.S.A. 95, 14769-14774. doi: 10.1073/pnas.95.25.14769
94. Wada, T., Sakai, N., Matsushima, K., and Kaneko, S. (2007). Fibrocytes: a new insight into kidney fibrosis. Kidney Int. 72, 269-273. doi: 10.1038/sj.ki.5002325
95. Wang, B., Herman-Edelstein, M., Koh, P., Burns, W., Jandeleit-Dahm, K., Watson, A., et al. (2010). E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 59, 1794-1802. doi: 10.2337/db09-1736
96. Wang, B., Jha, J. C., Hagiwara, S., McClelland, A. D., Jandeleit-Dahm, K., Thomas, M. C., et al. (2014). Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 85, 352-361. doi: 10.1038/ki.2013.372
97. Wang, B., Koh, P., Winbanks, C., Coughlan, M. T., McClelland, A., Watson, A., et al. (2011). miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 60, 280-287. doi: 10.2337/db10-0892
98. Wang, J., Gao, Y., Ma, M., Li, M., Zou, D., Yang, J., et al. (2013). Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem. Biophys. 67, 537-546. doi: 10.1007/s12013-013-9539-2
99. Wang, S., de Caestecker, M., Kopp, J., Mitu, G., Lapage, J., and Hirschberg, R. (2006a). Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 17, 2504-2512. doi: 10.1681/ASN.2006030278
100. Wang, W., Huang, X. R., Canlas, E., Oka, K., Truong, L. D., Deng, C., et al. (2006b). Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ. Res. 98, 1032-1039. doi: 10.1161/01.RES.0000218782.52610.dc
101. Wei, X., Xia, Y., Li, F., Tang, Y., Nie, J., Liu, Y., et al. (2013). Kindlin-2 mediates activation of TGF-beta/Smad signaling and renal fibrosis. J. Am. Soc. Nephrol. 24, 1387-1398. doi: 10.1681/ASN.2012101041
102. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347. doi: 10.1038/370341a0
103. Wu, C. F., Chiang, W. C., Lai, C. F., Chang, F. C., Chen, Y. T., Chou, Y. H., et al. (2013). Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am. J. Pathol. 182, 118-131. doi: 10.1016/j.ajpath.2012.09.009
104. Wynn, T. A., and Ramalingam, T. R. (2012). Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040. doi: 10.1038/nm.2807
105. Xavier, S., Vasko, R., Matsumoto, K., Zullo, J. A., Chen, R., Maizel, J., et al. (2014). Curtailing endothelial TGF-beta signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J. Am. Soc. Nephrol. doi: 10.1681/ASN.2013101137. [Epub ahead of print].
106. Xiao, J., Meng, X. M., Huang, X. R., Chung, A. C., Feng, Y. L., Hui, D. S., et al. (2012). miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol. Ther. 20, 1251-1260. doi: 10.1038/mt.2012.36
107. Xiong, M., Jiang, L., Zhou, Y., Qiu, W., Fang, L., Tan, R., et al. (2012). The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am. J. Physiol. Renal Physiol. 302, F369-F379. doi: 10.1152/ajprenal.00268.2011
108. Xu, X., Kriegel, A. J., Liu, Y., Usa, K., Mladinov, D., Liu, H., et al. (2012). Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int. 82, 1167-1175. doi: 10.1038/ki.2012.241
109. Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., et al. (1996). Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 49, 461-469. doi: 10.1038/ki.1996.65
110. Yang, F., Chung, A. C., Huang, X. R., and Lan, H. Y. (2009). Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54, 877-884. doi: 10.1161/HYPERTENSIONAHA.109.136531
111. Yang, F., Huang, X. R., Chung, A. C., Hou, C. C., Lai, K. N., and Lan, H. Y. (2010). Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J. Pathol. 221, 390-401. doi: 10.1002/path.2721
112. Yang, J., Zhang, X., Li, Y., and Liu, Y. (2003a). Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta1 signaling. J. Am. Soc. Nephrol. 14, 3167-3177. doi: 10.1097/01.ASN.0000099373.33259.B2
113. Yang, Y. C., Piek, E., Zavadil, J., Liang, D., Xie, D., Heyer, J., et al. (2003b). Hierarchical model of gene regulation by transforming growth factor beta. Proc. Natl. Acad. Sci. U.S.A. 100, 10269-10274. doi: 10.1073/pnas.1834070100
114. Yuan, W., and Varga, J. (2001). Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 276, 38502-38510. doi: 10.1074/jbc.M107081200
115. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M., and Kalluri, R. (2008). Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287. doi: 10.1681/ASN.2008050513
116. Zeisberg, M., Hanai, J., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., et al. (2003). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968. doi: 10.1038/nm888
117. Zhong, X., Chung, A. C., Chen, H. Y., Dong, Y., Meng, X. M., Li, R., et al. (2013). miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56, 663-674. doi: 10.1007/s00125-012-2804-x
118. Zhong, X., Chung, A. C., Chen, H. Y., Meng, X. M., and Lan, H. Y. (2011). Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 22, 1668-1681. doi: 10.1681/ASN.2010111168
119. Zhou, L., Fu, P., Huang, X. R., Liu, F., Chung, A. C., Lai, K. N., et al. (2010). Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Renal Physiol. 298, F1006-F1017. doi: 10.1152/ajprenal.00675.2009
120. Zhu, H. J., Iaria, J., and Sizeland, A. M. (1999). Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J. Biol. Chem. 274, 32258-32264. doi: 10.1074/jbc.274.45.32258